BioReliance launches novel genotoxicity screen

PRLog (Press Release) – Oct 24, 2007 – BioReliance (Rockville, Maryland) has contracted with Gentronix (Manchester, UK) to offer its GreenScreen HC in vitro assay as a major part of BioReliance’s portfolio of genotoxicity screening services.

Use of GreenScreen HC in conjunction with Ames II assays allows testing for genotoxic potential earlier in the preclinical development process, using only a few milligrammes of test compound instead of the gramme quantities required by current ICH regulatory tests.  The method also minimises false positives, notes David Bruning, BioReliance’s senior director, toxicology operations.  The assay can detect multiple mechanistic classes of genotoxic agents, including aneugens, and is easily adapted to automatic robotic platforms.

GreenScreen HC is a unique human cell-based genotoxicity screening assay that links the regulation of the human growth arrest and DNA damage (GADD45a) gene to the production of green fluorescent protein (GFP).  Cells that have suffered DNA damage following exposure to a test compound express higher levels of detectable GFP. Article submitted by www.jobs4dd.com.